Viridian Therapeutics, Inc.\DE (VRDN) Invested Capital: 2014-2025
Historic Invested Capital for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Sep 2025 value amounting to $523.9 million.
- Viridian Therapeutics, Inc.\DE's Invested Capital fell 28.04% to $523.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $523.9 million, marking a year-over-year decrease of 28.04%. This contributed to the annual value of $692.2 million for FY2024, which is 49.76% up from last year.
- According to the latest figures from Q3 2025, Viridian Therapeutics, Inc.\DE's Invested Capital is $523.9 million, which was down 2.26% from $536.0 million recorded in Q2 2025.
- Viridian Therapeutics, Inc.\DE's 5-year Invested Capital high stood at $728.0 million for Q3 2024, and its period low was $98.9 million during Q2 2021.
- Its 3-year average for Invested Capital is $518.1 million, with a median of $536.0 million in 2025.
- Per our database at Business Quant, Viridian Therapeutics, Inc.\DE's Invested Capital skyrocketed by 872.30% in 2021 and then decreased by 28.04% in 2025.
- Over the past 5 years, Viridian Therapeutics, Inc.\DE's Invested Capital (Quarterly) stood at $187.7 million in 2021, then spiked by 112.93% to $399.7 million in 2022, then grew by 15.64% to $462.2 million in 2023, then spiked by 49.76% to $692.2 million in 2024, then dropped by 28.04% to $523.9 million in 2025.
- Its Invested Capital stands at $523.9 million for Q3 2025, versus $536.0 million for Q2 2025 and $625.2 million for Q1 2025.